Articles
| Open Access | THE EFFECT OF THE ANTIOXIDANT DIBUNOL ON THE LIPID PROFILE OF BLOOD SERUM IN RABBITS WITH EXPERIMENTAL ATHEROSCLEROSIS
Tayirova Guldona Sanjarbekovna,Saydullaev Toyirjon , Student of the 2nd year, Faculty of Medicine, General Medicine Department, Andijan Branch of Kokand University/Scientific Advisor: Head of the Department of Medical Biology and Histology, ADTI, PhD in Medical Sciences, Associate ProfessorAbstract
Atherosclerosis is a widespread and severe systemic disease and remains a leading cause of cardiovascular morbidity and mortality. This study aimed to investigate the effect of the antioxidant dibunol on the serum lipid profile in rabbits with experimentally induced atherosclerosis. The results demonstrated that dibunol significantly reduced serum cholesterol, triglycerides, and beta-lipoprotein levels, confirming its potential for atherosclerosis prevention and therapy.
Keywords
Atherosclerosis, ischemic heart disease, antioxidant, dibunol, lipid metabolism, cholesterol, triglycerides, beta-lipoproteins, experimental model, prevention.
References
Ross, R. (1999). Atherosclerosis - an inflammatory disease. New England Journal of Medicine, 340(2), 115–126.
Libby, P. (2002). Inflammation in atherosclerosis. Nature, 420(6917), 868–874.
Ross, R. (1999). Atherosclerosis—An Inflammatory Disease. New England Journal of Medicine, 340(2), 115–126. doi:10.1056/NEJM199901143400207
Libby, P., Ridker, P.M., Hansson, G.K. (2011). Inflammation in Atherosclerosis: From Pathophysiology to Practice. Journal of the American College of Cardiology, 54(23), 2129–2138. doi:10.1016/j.jacc.2009.09.009
Kumar, V., Abbas, A.K., Aster, J.C. (2020). Robbins & Cotran Pathologic Basis of Disease. 10th Ed. Elsevier.
Jo‘raqulov, Sh.R., Alimov, A.A. Propedeutics of Internal Diseases. – Tashkent: “Tibbiyot” Publishing, 2018. – p. 420.
Mamatqulov, A., Yusupova, M.X. Clinical Therapy: Cardiovascular Diseases. – Tashkent: “Science and Technology”, 2020. – p. 368.
Article Statistics
Downloads
Copyright License
This work is licensed under a Creative Commons Attribution 4.0 International License.